Evinacumab for Homozygous Familial Hypercholesterolemia
Frederick J. Raal(University of the Witwatersrand), Daniel Gaudet(Brigham and Women's Hospital), Shazia Ali(Regeneron (United States)), David M. Weinreich(Regeneron (United States)), Robert Pordy(Inserm), Paolo Rubba(Cardiovascular Institute of the South), Robert S. Rosenson(Mount Sinai Hospital), Nagwa Khilla(Regeneron (United States)), Laurens F. Reeskamp(Cardiovascular Institute of the South), Poulabi Banerjee(Cardiovascular Institute of the South), John J.P. Kastelein(QRx Pharma (United States)), George D. Yancopoulos(Regeneron (United States)), Yi Zhang(Regeneron (United States)), Daniel A. Gipe(Regeneron (United States)), Kuo‐Chen Chan(Regeneron (United States)), G. Kees Hovingh(Novo Nordisk (Denmark))
Cited by 763
Related Papers
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
|New England Journal of Medicine|2017|9.1k
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel
|European Heart Journal|2017|3.8k
Vascular-specific growth factors and blood vessel formation
|Nature|2000|3.7k
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
|New England Journal of Medicine|2018|3.5k